Stockreport

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals, Inc.  (AGIO) 
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.agios.com/investor-overview
PDF – Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO® in Newly Diagnosed AML Patients – CAMBRIDGE, Mass., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Agio [Read more]